NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.
The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.
The partners will further develop Vitro's Vitrogrow cell culture medium, human hepatocytes, and industrially-adopted bioluminescent readout system for detecting liver toxicity and drug-induced liver injury in drugs and biologics that are in the development stage. The partners also intend to expand HemoGenix's LumiSTEM platform for other cell-specific toxicity assays such as heart, kidney, and neuronal cells.
Financial and other terms of the agreement were not disclosed.